(Q36040879)

11 August 2017

1 reference

title

Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs (English)

1 reference

11 August 2017

Rolf Mentlein

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

Expert Opinion on Investigational Drugs

11 August 2017

published in

1 reference

11 August 2017

volume

14

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

57-64

1 reference

The glucagon-like peptides

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Gut peptides in the treatment of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Incretins, insulin secretion and Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Production and characterization of four anti-neuropeptide Y monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

21 January 2018

Cell-surface peptidases

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

CD26 expression determines lung metastasis in mutant F344 rats: involvement of NK cell function and soluble CD26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

GLP-1 inhibition of pancreatic islet cell apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T-cell activation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Prolyl peptidases: a serine protease subfamily with high potential for drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.57

21 January 2018

Identifiers

DOI

10.1517/13543784.14.1.57

1 reference

release_jyuvla4xajhg7pqlwmi2rophau

11 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jyuvla4xajhg7pqlwmi2rophau

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference